Home/Filings/4/0000899243-21-049100
4//SEC Filing

Rubin Jami 4

Accession 0000899243-21-049100

CIK 0001843762other

Filed

Dec 19, 7:00 PM ET

Accepted

Dec 20, 9:58 PM ET

Size

8.3 KB

Accession

0000899243-21-049100

Insider Transaction Report

Form 4
Period: 2021-12-17
Rubin Jami
Chief Financial Officer
Transactions
  • Award

    Common Stock

    2021-12-17+2,194,5002,194,500 total
  • Award

    Earn-out Shares

    2021-12-17+300,618300,618 total
    Exp: 2024-12-17Common Stock (300,618 underlying)
Footnotes (2)
  • [F1]On December 17, 2021, upon consummation of the transactions (the "Closing" of the "Business Combination") contemplated by the Agreement and Plan of Merger dated August 5, 2021 (the "Merger Agreement") by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc., "Legacy EQRx"), each share of Legacy EQRx capital stock was exchanged, pursuant to the Merger Agreement, for shares of the Issuer's Common Stock.
  • [F2]Upon consummation of the Business Combination, the Reporting Person received the right to acquire an aggregate of 300,618 shares of the Issuer's Common Stock (the "Earn-out Shares"), (i) 210,433 of which will be released from escrow if the value weighted average price ("VWAP") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 90,185 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment per the terms of the Merger Agreement.

Issuer

EQRx, Inc.

CIK 0001843762

Entity typeother

Related Parties

1
  • filerCIK 0001816484

Filing Metadata

Form type
4
Filed
Dec 19, 7:00 PM ET
Accepted
Dec 20, 9:58 PM ET
Size
8.3 KB